Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Co.'s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Co.'s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. We show 26 historical shares outstanding datapoints in our EQ shares outstanding history coverage, used to compute EQ market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EQ market cap history over the course of time is important for investors
interested in comparing EQ's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EQ versus a peer is one thing; comparing
EQ market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EQ can fluctuate over the course of history.
With this page we aim to empower investors researching EQ by allowing them to research the EQ market cap history. |
Free EQ Email Alerts:
Video: The Importance of Market Cap
